FDAnews
www.fdanews.com/articles/102092-orexigen-begins-obesity-trial

Orexigen Begins Obesity Trial

December 11, 2007

Orexigen Therapeutics has started the fourth trial in its Phase III clinical trial program for Contrave as a treatment for obesity.

The 56-week trial will assess the safety, tolerability and efficacy of Contrave in healthy, nondiabetic, obese patients. At week 28, nonresponding patients will be rerandomized to receive either a higher dose of Contrave or continue on their original doses.

Gary Tollefson, Orexigen’s president and CEO, said the company intends to submit a new drug application for Contrave in the second half of 2009.